FDA Extends Xgeva Approval to Include Myeloma Patients with Bone Lesions
The U.S. Food and Drug Administration (FDA) has agreed…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Dual-targeted CAR T-cell Therapy Shows Promising Anti-tumor Response in Mice
A preclinical study has shown that a new dual-targeting APRIL…
Janssen and Legend Biotech Joining Forces to Advance Myeloma CAR T-cell Therapy
Janssen Biotech and China’s Legend Biotech are teaming…
BioLineRx Readies Phase 3 Myeloma Trial to Mobilize Stem Cells for Transplant
BioLineRx has launched a Phase 3 trial to…
Biomarker Found That Detects Myeloma Patients Who Will Benefit from Stem Cell Transplant
A collaboration between GNS Healthcare and the Multiple…
CellProtect Receives EU Orphan Drug Status for Treatment of Multiple Myeloma
The European Commission has granted orphan drug status to…
